Pharmaceutical Executive, November 2021 Issue (PDF)

FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.

FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.

Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.

Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.

Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.

Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.

Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.